ReviewCurrent diabetes reports2012
Anti-fibrosis therapy and diabetic nephropathy.
Review in Current diabetes reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Key Genetic Components of Fibrosis in Diabetic Nephropathy: An Updated Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- Trial
- Integrative bioinformatics analysis of Lianmei granules in diabetic nephropathy: Epidemiological and molecular insights.Medicine · 2026Article
- Heterogeneity characterization and key pathogenic genes screening based on diabetic nephropathy microenvironment.Open life sciences · 2026Article
- Integrating network pharmacology, transcriptomics, molecular docking and in vitro experiments to investigate the material basis and mechanism of Liuwei Dihuang Pills for treating diabetic nephropathy.Food & nutrition research · 2025Article
- Article
- Advances of berberine against metabolic syndrome-associated kidney disease: Regarding effect and mechanism.Frontiers in pharmacology · 2023Review
- Hemoglobin A1c and Angiographic Severity with Coronary Artery Disease: A Cross-Sectional Study.International journal of general medicine · 2022Article
- Article
- Baicalin reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal injury in type 1 diabetic mouse model.Cell cycle (Georgetown, Tex.) · 2020Article
- The utility of magnetic resonance imaging for noninvasive evaluation of diabetic nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2020Article
- WJ-39, an Aldose Reductase Inhibitor, Ameliorates Renal Lesions in Diabetic Nephropathy by Activating Nrf2 Signaling.Oxidative medicine and cellular longevity · 2020Article
- PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease.The Journal of clinical investigation · 2019Article
- Long non-coding RNA MEG3 impacts diabetic nephropathy progression through sponging miR-145.American journal of translational research · 2019Article
- RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology · 2019Article
- Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2017Review
- Role and New Insights of Pirfenidone in Fibrotic Diseases.International journal of medical sciences · 2015Review
- Diabetes and immunity to tuberculosis.European journal of immunology · 2014Review
- Influence of vanadium-organic ligands treatment on selected metal levels in kidneys of STZ rats.Biological trace element research · 2013Article
- Korean red ginseng extract alleviates advanced glycation end product-mediated renal injury.Journal of ginseng research · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is rapidly becoming a global health issue that may overtake cancer during the next two decades as it covertly affects multiple organ systems that goes undiagnosed long after the onset. A number of complications are associated with poorly controlled hyperglycemia. Diabetic nephropathy is one of the most common complications of diabetes mellitus. Other than angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blocker (ARB) there is not much in the armamentarium with which to treat patients with overt diabetic nephropathy. Research points towards a multifactorial etiology and complex interplay of several pathogenic pathways that can contribute to the declining kidney function in diabetes. Patients with diabetic nephropathy (and with any chronic kidney disease) eventually develop kidney fibrosis. Despite the financial and labor investment spent on determining the basic mechanism of fibrosis, not much progress has been made in terms of therapeutic targets available to us today. This may be in part due to paucity in the experimental animal models available. However, there now seems to be a concerted effort from several pharmaceutical companies to develop a drug that would halt/delay the process of fibrosis, if not reverse it. This review discusses the current state of research in the field while staying within the context of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.